[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer
A phase 3 trial of Florastamin F-18 run by FutureChem, active.
Overview
[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer is a phase 3 interventional study registered as NCT05936658 by FutureChem, with 138 participants enrolled, started 2023-05-08. Conditions listed: High Risk Prostate Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialEvaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis
Shares FutureChem, Florastamin F-18, Fluorine-18, Prostate cancer.
- TrialStudy of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares Florastamin F-18, Fluorine-18, Prostate cancer.
- JournalNuclear Medicine and Molecular Imaging
Shares FutureChem, Florastamin F-18.
- InstitutionKorean Society of Nuclear Medicine
Shares FutureChem, Florastamin F-18, Fluorine-18.
- TrialA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Shares Fluorine-18, Prostate cancer.
- TrialAnti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Shares Fluorine-18, Prostate cancer.
- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Shares Fluorine-18, Prostate cancer.
- AgentCholine C-11
Shares Fluorine-18, Prostate cancer.